Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ChemoCentryx, Inc.

https://www.chemocentryx.com/

Latest From ChemoCentryx, Inc.

Seres Aims To File C. Diff Microbiome Drug On Single Pivotal Trial

Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.

Clinical Trials Drug Approval Standards

Virus-Hit Astellas Cuts Forecast

Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.

Coronavirus COVID-19 Commercial

Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales

The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus. 

Sales & Earnings Coronavirus COVID-19

Keeping Track: Kite’s Tecartus Is Third CAR-T With US FDA Approval; Submissions Round-Up

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register